ResearchTolerability and Outcomes With Serial Cycles of 28 Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid Leukemia
ResearchTolerability and Outcomes With Serial Cycles of 28 Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid Leukemia.
ResearchKnown Prognostic Models Fail to Predict Outcomes for Venetoclax and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia: A Single-Center Retrospective Analysis
ResearchKnown Prognostic Models Fail to Predict Outcomes for Venetoclax and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia: A Single-Center Retrospective Analysis.